Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism

Diabetes Research and Clinical Practice

Volumn 50, Issue 2, 2000, Pages 127-136

  Anwaar, I ^a   Gottsater A ^a   Eriksson, K F ^a   Jacobsson, L ^a   Lindgarde F ^a   Mattiasson, I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cGMP; Endothelin 1; IGT; Neopterin; Type 2 diabetes

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CYCLIC GMP; ENDOTHELIN 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NEOPTERIN; NITRIC OXIDE; PROSTACYCLIN;

ADULT; AGED; ARTICLE; CELL DAMAGE; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; THROMBOCYTE AGGREGATION;

AGED; BLOOD GLUCOSE; BLOOD PLATELETS; BLOOD PRESSURE; CHOLESTEROL; CYCLIC GMP; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIN-1; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LEUKOCYTE COUNT; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; REFERENCE VALUES; SMOKING; VASCULAR DISEASES;

EID: 0342521474     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00190-X     Document Type: Article

References (62)

1. Yanagisawa M., Kurihara H., Kimura S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 263:1976;663-665.
3. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
4. Radomski M.W., Palmer R.M.J., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 92:1987;181-187.
5. Ware J.A., Heistad D.D. Platelet-endothelium interactions. N. Engl. J. Med. 328:1993;628-635.
6. Radomski M.W., Palmer R.M.J., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 2:1987;1057-1058.
7. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA. 88:1991;4651-4655.
8. Miyauchi T., Yanagisawa M., Tomizawa T. et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 2:1989;53-54.
9. Rodeheffer R.J., Lerman A., Heublein D.M., Burnett J.C. Jr Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin. Proc. 67:1992;719-724.
10. Koyama H., Tabata T., Nishzawa Y., Inoue T., Morii H., Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1:1989;991-992.
11. Firth J.D., Ratcliffe P.J., Raine A.E., Ledingham J.D. Endothelin: an important factor in acute renal failure? Lancet. 2:1988;1179-1182.
12. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 33:1990;306-310.
13. Laurenti O., Vingolo E.M., Desideri G.B. et al. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp. Clin. Endocrinol. Diabetes. 105(Suppl. 2):1997;40-42.
14. Kano K., Hirata Y., Shichiri M., Marumo F. Plasma endothelin-1 levels in patients with diabetes mellitus with or wihout vascular complication. J. Cardio. Vasc. Pharmacol. 17(Suppl. 7):1991;S475-S476.
15. Abiru T., Watanabe Y., Kamata K., Miyata N., Kasuya Y. Decrease in endothelium-dependent relaxation and levels of cyclic nucleotides in aorta from rabbits with alloxan-induced diabetes. Res. Commun. Chem. Pathol. Pharmacol. 68:1990;13-25.
16. Mayhan W.G. Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am. J. Physiol. 256:1989;H621-H625.
17. Morris S.J., Shore A.C., Tooke J.E. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia. 38:1995;1337-1344.
18. Watts G.F., O'Brien S.F., Silvester W., Millar J.A. Impaired endothelium-dependent and -independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidemia. Clin. Sci. Colch. 91:1996;567-573.
19. Neri S., Bruno C.M., Leotto C., D'Amico R.A., Pennisi G., Ierna D. Early endothelial alterations in non-insulin dependent diabetes mellitus. Int. J. Clin. Lab. Res. 28:1998;100-103.
20. Hattori Y., Kawasaki H., Abe K., Kanno M. Superoxide dismutase recovers altered endothlium-dependent relaxation in diabetic rat aorta. Am. J. Physiol. 261:1991;H1086-H1094.
21. Tesfamariam B., Brown M.L., Cohen R.A. Aldose reductase and myo-inositol in endothelial cell dysfunction caused by elevated glucose. J. Pharmacol. Exp. Ther. 263:1992;153-157.
22. Fujii K., Soma M., Huang Y.S., Manku M.S., Horrobin D.F. Increased release of prostaglandins from the mesenteric vascular bed of diabetic animals: the effects of glucose and insulin. Prostaglandins Leukot. Med. 24:1986;151-161.
23. Davi G., Rini G.B., Averna M. et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb. Res. 26:1982;359-370.
24. Butkus A., Skrinska V.A., Schumacher O.P. Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb. Res. 19:1980;211-223.
25. Marhoffer W., Stein M., Maeser E., Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 15:1992;256-260.
26. Delamaire M., Maugendr D., Moreno M., Le Goff M.C., Allannic H., Genetet B. Impaired leucocyte functions in diabetic patients. Diabet. Med. 14:1997;29-34.
27. Huber C., Batchelor J.R., Fuchs D. et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160:1984;310-316.
28. Fuchs D., Hausen A., Reibnegger G., Werner E.R., Wachter H. Neopterin in clinical medicine. Lancet. 1:1988;702.
29. Tatzber F., Rabl H., Koriska K. et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 89:1991;203-208.
30. Schumacher M., Eber B., Tatzber F., Kaufmann P., Esterbauer H., Klein W. Neopterin levels in patients with coronary artery disease. Atherosclerosis. 94:1992;87-88.
31. Anwaar I., Gottsäter A., Ohlsson K., Lindgärde F., Mattiasson I. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc. Dis. 8:1998;310-319.
32. Anwaar I., Gottsäter A., Lindgarde F., Mattiasson I. Increasing plasma neopterin and persistent plasma endothelin during follow-up after acute cerebral ischemia. Angiology. 50:1999;1-8.
33. Berglund G., Eriksson K.F., Israelsson B. et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmo Preventive Project. J. Int. Med. 239:1996;489-497.
34. Eriksson K.F., Lindgärde F. Prevention of type 2 (non-insulin dependent) diabetes mellitus by diet and physical exercise. Diabetologia. 34:1991;891-898.
35. Alberti K.G.M.M., Zimmet P.Z. For the WHO Consultation Group. Definition and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15:1998;539-553.
36. Jeppsson J.O., Jerntorp P., Sundkvist G., Englund H., Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin. Chem. 32:1986;1867-1872.
37. Burstein M., Scholnick H.R., Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid Res. 11:1970;583-595.
38. Perfetto F., Tarquini R., de Leonardis V., Piluso A., Lombardi V., Tarquini B. Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients. Acta Diabetol. 32:1995;263-267.
39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
40. Roshan B., Tofler G.H., Weinrauch L.A. et al. Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism. 49:2000;88-91.
41. Iwase E., Tawata M., Aida K. et al. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism. 47:1998;699-705.
42. Knobler H., Savion N., Shenkman B., Kotev Emeth S., Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb. Res. 90:1998;181-190.
43. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:1993;2002-2012.
44. Callaerts-Vegh Z., Wenk M., Goebbels U. et al. Influence of intensive physical training on urinary nitrate elimination and plasma endothelin-1 levels in patients with congestive heart failure. J. Cardiopulm. Rehabil. 18:1998;450-457.
45. Sakamoto S., Minami K., Niwa Y. et al. Effects of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous NIDDM. Diabetes. 47:1998;82-86.
46. Eriksson K.F., Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise. Diabetologia. 41:1998;1010-1016.
47. Komers R., Allen T.J., Cooper M.E. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes. 43:1994;1190-1197.
48. Catalano M., Carzaniga G., Perilli E. et al. Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus. Vasc. Med. 2:1997;302-305.
49. Martina V., Bruno G.A., Trucco F. et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb. Haemost. 79:1998;520-522.
50. Rabini R.A., Staffolani R., Furnelli P., Mutus B., Curatola G., Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia. 41:1998;101-104.
51. Amado J.A., Salas E., Botana M.A., Poveda J.J., Berrazueta J.R. Low levels of intraplatelet cGMP in IDDM. Diabetes Care. 16:1993;809-811.
52. Cohen R.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation. 92:1995;3337-3349.
53. Watanabe H., Kakihana M., Ohtsuka S., Enomoto T., Yasui K., Sugishita Y. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation. 88:1993;29-36.
54. Gottsäter A., Anwaar I., Hedblad B., Wallmark A., Lindgärde F., Mattiasson I. Higher intraplatelet cyclic nucleotide levels in stroke than in asymptomatic carotid atherosclerosis and controls (abstract). Haemostasis. 26(Suppl. 3):1996;543.
55. Faraci F.M., Brian J.E. Nitric oxide and the cerebral circulation. Stroke. 25:1994;692-703.
56. Kanazawa K., Kawashima S., Mikami S. et al. Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am. J. Pathol. 148:1996;1949-1956.
57. Chen S.Y., Yu B.J., Liang Y.Q., Lin W.D. Platelet aggregation, platelet cAMP levels and thromboxane B2 synthesis in patients with diabetes mellitus. Chin. Med. J. 103:1990;312-318.
58. Garcia Unzueta M.T., Montalban C., Pesquera C., Berrazueta J.R., Amado J.A. Platelet adrenomodullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes Care. 21:1998;999-1003.
59. Abdel-Halim S.M., Guenifi A., He B. et al. Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression os AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes. 47:1998;498-504.
60. Fisher T.C., Meiselmann H.J. Polymorphonuclear leukocytes in ischemic vascular disease. Thromb. Res. 74(Suppl. 1):1994;S21-S34.
61. Salozhin K.V., Nasonov E.L., Sura V.V., Aleksandrova E.N., Gracheva L.A. Study of lymphocyte subpopulations and the expression of activation markers in diabetes mellitus types 1 and 2. Klin. Med. 67:1989;118-121.
62. Manna R., Salvatore M., Di Leo M.A.S. et al. Relationship between urinary neopterin excretion and islet cell antibodies in type 1 (insulin-dependent) diabetes. Diabetes Res. 17:1991;33-36.